HarrisMIFlegalKMCowieCCEberhardtMSGoldsteinDELittleRR. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care1998; 21: 518–524.
2.
HaffnerSMSternMPHazudaHPMitchellBDPattersonJK. Cardiovascular risk factors in confirmed prediabetic individuals.. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?JAMA1990; 263: 2893–2898.
3.
SternMP. Diabetes and cardiovascular disease. The ‘common soil' hypothesis. Diabetes1995; 44: 369–3674.
4.
HuFBStampferMJHaffnerSMSolomonCGWillettWCMansonJE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care2002; 25: 1129–1134.
5.
HopperIBillahBSkibaMKrumH. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with pre-diabetes: meta-analysis of randomized controlled clinical trials. Eur J Cardiovasc Prev Rehabil2011; 18: 813–823.
6.
KnowlerWCBarrett-ConnorEFowlerSEHammanRFLachinJMWalkerEA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393–403.
7.
OrchardTJTemprosaMGoldbergRHaffnerSRatnerRMarcovinaS. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med2005; 142: 611–619.
8.
McMurrayJJHolmanRRHaffnerSMBethelMAHolzhauerBHuaTA. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med2010; 362: 1477–1490.
9.
van DamRMLiTSpiegelmanDFrancoOHHuFB. Combined impact of lifestyle factors on mortality: prospective cohort study in US women. BMJ2008; 337: a1440–a1440.
10.
ChiassonJLJosseRGGomisRHanefeldMKarasikALaaksoM. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002; 359: 2072–2077.
11.
ZinmanBHarrisSBNeumanJGersteinHCRetnakaranRRRaboudJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet2010; 376: 103–111.
12.
ScheenAJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?Diabetes Metab2007; 33: 3–12.
13.
BoussageonRBejan-AngoulvantTSaadatian-ElahiMLafontSBergeonneauCKassaïB. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ2011; 343: d4169–d4169.
